GEMCITABINE is a chemotherapy drug given through a vein. It works by stopping cancer cells from copying their DNA, which helps slow or shrink tumors. In this study it is one of the standard chemotherapy options that doctors may choose for patients in the control group.

CARBOPLATIN is another chemotherapy medicine administered intravenously. It damages the DNA inside cancer cells, making it harder for them to grow and spread. It is also part of the usual chemotherapy choices that can be used in the control arm of the trial.

TOPOTECAN is a chemotherapy agent given by IV. It interferes with an enzyme needed for DNA replication, helping to stop cancer cells from dividing. It may be selected by investigators as one of the chemotherapy options for patients in the control group.

PACLITAXEL is a chemotherapy drug delivered through a vein. It blocks the ability of cancer cells to form the structures they need to divide, which can slow tumor growth. It is another possible chemotherapy choice for the control arm.

DOXORUBICIN is an IV chemotherapy medication that works by inserting itself into DNA and preventing cancer cells from multiplying. It is also among the standard chemotherapy options that doctors might use for patients in the control group.

MIRVETUXIMAB SORAVTANSINE is a targeted therapy that combines an antibody with a cell‑killing drug. The antibody part seeks out a protein often found on ovarian cancer cells, delivering the toxin directly to those cells while sparing most normal cells. In the trial it can be chosen as the control treatment for patients with platinum‑resistant disease.

BEVACIZUMAB is a medication that blocks a protein called VEGF, which tumors use to grow new blood vessels. By stopping new blood vessels from forming, it can help slow tumor growth. In this study it is given together with either the experimental drug or standard chemotherapy to see if it improves outcomes.

LY4170156 (also called Sofetabart Mipitecan) is an experimental drug being tested in this trial. It belongs to a class of medicines that interfere with an enzyme needed for DNA replication, aiming to stop cancer cells from dividing. In Part A it is compared alone against standard chemotherapy or mirvetuximab soravtansine, and in Part B it is given together with bevacizumab to see if the combination works better than standard chemotherapy plus bevacizumab.

Fallopian Tube Neoplasms – These are abnormal growths that develop in the lining of the fallopian tubes. They may start as small growths and gradually enlarge, sometimes causing blockage of the tube. As they grow, they can extend into nearby pelvic organs or spread through the lining of the abdomen.
Peritoneal Neoplasms – These are tumors that arise on the surface that lines the abdominal cavity. They often begin as localized patches and can expand across the peritoneal surface. Over time they may involve surrounding organs and spread within the abdominal space.
Ovarian Neoplasms – These are abnormal tissue growths that originate in the ovaries. They typically start inside the ovary and can increase in size, potentially distorting the organ. With progression, they may extend to the pelvic region, the abdomen, or travel through lymph channels.
Neoplasm Metastasis – This term describes the process by which cancer cells move from an original tumor to form new growths in other parts of the body. Cells break away, travel through blood or lymph vessels, and settle in distant tissues. The new tumors then grow in their new location, following a similar pattern of expansion.